Talacotuzumab clinical trials
Also written JNJ-56022473 and CSL362.
How each study uses talacotuzumab is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Approvals
The first approval found in each region, with its record
- United States
- Not in FDA's approval records
- European Union
- Not in EMA's list of EU-wide authorizations
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
How studies write it
Studies that test it under each name
Studies by the year they started
5 studies that test it; most in 2017 (2)
| Year | Studies |
|---|---|
| 2012 | 1 |
| 2015 | 1 |
| 2016 | 1 |
| 2017 | 2 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 4 · Other 1
Janssen Research & Development, LLC (3) · CSL Limited (1) · GWT-TUD GmbH (1)
Often tested with
Tested in the same studies.
Studies
Open first, then newest update. How each study uses talacotuzumab is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 5
- Study to Separately Evaluate the Activity of Talacotuzumab (JNJ-56022473) or Daratumumab in Transfusion-Dependent Participants With Low or Intermediate-1 Risk Myelodysplastic Syndromes (MDS) Who Are Relapsed or Refractory to Erythropoiesis-Stimulating Agent (ESA) TreatmentCompletedPhase 2Janssen Research & Development, LLCNCT03011034Written as Talacotuzumab
- An Efficacy and Safety Study of Decitabine (DACOGEN) Plus Talacotuzumab (JNJ-56022473; Anti CD123) Versus Decitabine (DACOGEN) Alone in Participants With Acute Myeloid Leukemia (AML) Ineligible for Intensive ChemotherapyCompletedPhase 2/3Janssen Research & Development, LLCNCT02472145Written as Talacotuzumab 9 mg/kg
- Single Agent JNJ-56022473 in MDS and AML Patients FAILING HYPOMETHYLATING AGENT BASED THERAPYTerminatedPhase 2GWT-TUD GmbHNCT02992860Written as JNJ-56022473
- A Study to Evaluate the Safety, Pharmacokinetics, and Pharmacodynamics of JNJ-56022473 in Subjects With Systemic Lupus ErythematosusWithdrawnPhase 1Janssen Research & Development, LLCNCT02920424Written as JNJ-56022473
- A Study of CSL362 in Patients With CD123+ Acute Myeloid Leukemia Currently in RemissionCompletedPhase 1CSL LimitedNCT01632852Written as CSL362
Codes
What other systems call talacotuzumab · ClinicalTrials.gg INT018446
- UNII (FDA) X8JR0I7JE1TALACOTUZUMABOne source FDA
- NCI Thesaurus C102784TalacotuzumabOne source FDA
| System | Code | Name there | Checked by |
|---|---|---|---|
| UNII (FDA) | X8JR0I7JE1 | TALACOTUZUMAB | One source FDA |
| NCI Thesaurus | C102784 | Talacotuzumab | One source FDA |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.